A Phase 4 interventional study of Etanercept and Methotrexate in Psoriasis and Arthritis, Psoriatic, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-28.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing etanercept in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. Etanercept · Arthritis, Psoriatic.
Among the 14 studies testing etanercept in Arthritis, Psoriatic, this one is the 11th largest by enrollment, is one of 4 that started in 2005, is one of 6 in phase 4, and was the 2nd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 14 studies testing etanercept in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
Etanercept: first FDA approval 1998 (ENBREL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 87 Arthritis, Psoriatic studies recruiting now, 52 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 105 across the 14 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
29 studies in Arthritis, Psoriatic by Pfizer: none open now, none under way, none of them phase 3. Of 29 finished, 22 (76%) have results posted.
Among the 29 studies in Arthritis, Psoriatic by Pfizer, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2005, is one of 3 in phase 4, and was the 1st registered.
Pfizer’s Arthritis, Psoriatic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing etanercept in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 29 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
This study's enrollment of 60 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Proportion of pts whose plaque psoriasis is cleared or almost cleared after 24 weeks.
Percentage improvement in PASI. Proportion of pts demonstrating PASI 50, 75
and 90. Time to clear or almost clear on PGA.
The record gives a start of Apr 2005, a primary completion of Aug 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Etanercept · Methotrexate
Wyeth is now a wholly owned subsidiary of Pfizer →